For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 79,159 | |||
| General and administrative | 18,896 | |||
| Total operating expenses | 98,055 | |||
| Loss from operations | -98,055 | |||
| Interest and other income, net | 11,084 | |||
| Net loss | -86,971 | |||
| Unrealized gain on marketable securities | 285 | |||
| Reclassification of net gains included in net loss | 54 | |||
| Total other comprehensive gain (loss) | 231 | |||
| Total comprehensive loss | -86,740 | |||
| Basic EPS | -2.38 | |||
| Diluted EPS | -2.38 | |||
| Basic Average Shares | 36,506,092 | |||
| Diluted Average Shares | 36,506,092 | |||
MBX Biosciences, Inc. (MBX)
MBX Biosciences, Inc. (MBX)